Evidence map›Paper›PMID 36172127›Full record

ArticlebioRxiv : the preprint server for biology2022

SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.

Wafaa B Alsoussi, Sameer K Malladi, Julian Q Zhou, Zhuoming Liu, Baoling Ying, Wooseob Kim, Aaron J Schmitz, Tingting Lei, Stephen C Horvath, Alexandria J Sturtz and 22 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 40 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 3 institutions in 1 country.

Wafaa B AlsoussiDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Sameer K MalladiDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Julian Q ZhouDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Zhuoming LiuDepartment of Molecular Microbiology, Washington University School of Medicine; St. Louis, MO, USA.
Baoling YingDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Wooseob KimDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Aaron J SchmitzDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Tingting LeiDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Stephen C HorvathDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Alexandria J SturtzDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Katherine M McIntireDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Birk EvavoldDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Fangjie HanDepartment of Emergency Medicine, Washington University School of Medicine; St. Louis, MO, USA.
Suzanne M ScheafferDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Isabella F FoxDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Luis Parra-RodriguezDivision of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine; St. Louis, MO, USA.
Raffael NachbagauerModerna, Inc.; Cambridge, MA, USA.
Biliana NestorovaModerna, Inc.; Cambridge, MA, USA.
Spyros ChalkiasModerna, Inc.; Cambridge, MA, USA.
Christopher W FarnsworthDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Michael K KlebertInfectious Disease Clinical Research Unit, Washington University School of Medicine; St. Louis, MO, USA.
Iskra PusicDivision of Oncology, Department of Medicine, Washington University School of Medicine; St. Louis, MO, USA.
Benjamin S StrnadMallinckrodt Institute of Radiology, Washington University School of Medicine; St. Louis, MO, USA.
William D MiddletonMallinckrodt Institute of Radiology, Washington University School of Medicine; St. Louis, MO, USA.
Sharlene A TeefeyMallinckrodt Institute of Radiology, Washington University School of Medicine; St. Louis, MO, USA.
Sean P J WhelanDepartment of Molecular Microbiology, Washington University School of Medicine; St. Louis, MO, USA.
Michael S DiamondDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Robert ParisModerna, Inc.; Cambridge, MA, USA.
Jane A O'HalloranDivision of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine; St. Louis, MO, USA.
Rachel M PrestiDivision of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine; St. Louis, MO, USA.
Jackson S TurnerDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Ali H EllebedyDepartment of Pathology and Immunology, Washington University School of Medicine; St. Louis, MO, USA.
Washington University in St. Louis · USModerna Therapeutics (United States) · USUniversity of Missouri–St. Louis · US

Funding

Household Respiratory Virus SARS-CoV-2 Transmission and Immunity Sub-Study (HRTS)U01AI144616 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GORDON, AUBREE L, THOMAS, PAUL G. · 2019 to 2025
$43.7M
Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0M
DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSESU01AI150747 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2020 to 2024
$5.9M
Programming Durable Immune Responses To VaccinationU01AI141990 · NIAID · WASHINGTON UNIVERSITY · PI Ali Hassan Ellebedy · 2019 to 2026
$5.3M
Structural interrogation of vaccine- and infection-induced B cell responsesR01AI168178 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Goran Bajic · 2022 to 2026
$3.9M
Mechanism and Inhibition of SARS-CoV-2 EntryR01AI163019 · NIAID · WASHINGTON UNIVERSITY · PI KIRCHHAUSEN, TOMAS, WHELAN, SEAN PJ · 2021 to 2025
$3.8M
NIAID NIH HHS R01 AI157155NIAID NIH HHS R01 AI163019NIAID NIH HHS R01 AI168178NIAID NIH HHS U01 AI141990NIAID NIH HHS U01 AI144616NIAID NIH HHS U01 AI150747
6 · The paper itself

Abstract

The primary two-dose SARS-CoV-2 mRNA vaccine series are strongly immunogenic in humans, but the emergence of highly infectious variants necessitated additional doses of these vaccines and the development of new variant-derived ones

Identifiers

PMID36172127
PMCPMC9516848
OpenAlexW4296910994

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.